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variables (age, marital status, education, employment, income,
comorbidity), older age, widowhood, lower education, retire-
ment, and comorbidity (Charlson > 2), were associated with
lower QoL (all p < 0.05). In multivariate analyses, all patient-
related variables explained 18–21% of the variance in scores.
With the addition of disease-related variables (treatment with
radical prostatectomy, radiation, or hormones; metastases,
Gleason score at diagnosis), the model explained 21–25% of the
variance. Patients currently on hormone treatment had lower
PORPUS-Ui and HUI3 scores than patients treated with hor-
mones in the past or never (p < 0.05). System-related variables
(year and county of diagnosis) contributed little to the explained
variance (1–3%). Symptom-related variables (PCI urinary,
sexual, bowel function) were the strongest predictors of QOL
(explaining 47–70% of the variance). CONCLUSION: Symp-
toms related to PC and its treatment have large effects on the
QoL of PC survivors. Although many variables are associated
with QoL, only prostate symptoms and comorbidity have inde-
pendent effects.
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OBJECTIVE: A multicenter phase III trial showed patients with
stage III or IV follicular lymphoma who achieved a partial or
complete remission after ﬁrst-line treatment receiving 90Y-
ibritumomab tiuxetan had signiﬁcantly longer PFS time as com-
pared to similar patients receiving no treatment. The objective of
this study was to determine the impact of 90Y-ibritumomab
tiuxetan on health-related quality of life. METHODS: Health-
related quality of life was assessed using EORTC QLQ-C30
version 2 and EuroQoL-5D (EQ-5D) questionnaires. These ques-
tionnaires were administered at screening, week 14 and every 6
months thereafter and ﬁnally at end of follow-up. Descriptive
statistics were used to compare scores across treatment groups.
The change in scores from baseline was also assessed by gender,
age and ﬁrst-line treatment. Mixed effects model was used to
assess the factors that were associated with ﬁnal scores of Visual
Analogue Scale (VAS) of EQ-5D.RESULTS:Nonotable treatment
differences were observed in the scores of EORTC QLQ-C30 (all
domains) scores across timepoints or changes from baseline. This
result was true for all sub-groups. The mean scores for EQ-5D at
screening and ﬁnal visit were 0.83 and 0.84 for 90Y-ibritumomab
tiuxetan and 0.84 and 0.83 for control arm. The mean VAS scores
at screening and ﬁnal visit were 77.52 and 77.64 for 90Y-
ibritumomab tiuxetan and 76.57 and 78.51 for control arm. An
analysis of factors associated with ﬁnal VAS scores showed that
baseline VAS scores affected ﬁnal VAS scores (p < 0.0001). CON-
CLUSION: There appears to be no difference in quality of life for
patients on 90Y-ibritumomab tiuxetan as compared to those in
control arm as measured by EORTC QLQ C-30 and EQ-5D
questionnaires. 90Y-ibritumomab tiuxetan prolongs PFS without
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OBJECTIVE: To quantify the impact of disease and its treatment
on patient-reported well-being, it is important to consider the
patient’s economic circumstances. This study explored the rela-
tionship between annual household income and health-related
psychological well-being among insured, long-term (>ﬁve years)
colorectal cancer (CRC) survivors with and without permanent
intestinal stomas. METHODS: This is a secondary analysis of
data collected as part of an NCI-funded study of health-related
quality of life (HRQOL) among CRC survivors, in which 681
respondents (52% response rate) completed a survey instrument
that included the modiﬁed City of Hope Quality of Life (mCOH-
QOL)–Ostomy questionnaire, SF-36 v2, and socio-demographic
items. Of these, 588 subjects provided income data and were
included in this analysis. The mCOH-QOL–Ostomy is based on
a four-dimension model of HRQOL (physical, psychological,
social, and spiritual well-being). For this analysis, the dependent
variable was the psychological well-being (PWB) score. Hierar-
chical linear regression was used to explore the unique contribu-
tion of income to the total variance of PWB over and above the
model that included the following independent variables: self-
reported physical health (SF-36v2 PCS), co-morbidity (Charlson-
Deyo), age, sex, race/ethnicity, education, partnered status, and
presence of an ostomy. RESULTS: After accounting for the pro-
portion of variance in PWB explained by the other independent
variables, the additional variance explained by income was sig-
niﬁcant (R2 increased from 0.228 to 0.250; p = 0.006). When
compared to those in the highest household income category
(>$100,000), subjects in the lowest income category (<$5000)
had a clinically meaningful 0.82 point lower PWB score on the
11-point scale. Signiﬁcant positive predictors of PWB were PCS
score, age, and absence of an ostomy. CONCLUSION: Although
the study design does not allow causal inference, these results
demonstrate a signiﬁcant relationship between income and PWB
that merits further consideration when attempting to interpret
patient-reported outcomes, particularly HRQOL.
PCN69
QUALITY OF LIFE IMPACT OF HOT FLUSHES IN MEN
RECEIVINGTREATMENT FOR PROSTATE CANCER
Nixon A1, Swinburn P1, Lloyd A1, Connolly MP2
1Oxford Outcomes Ltd, Oxford, Oxon, UK, 2Ferring International
Center, Saint-Prex, Switzerland
OBJECTIVE: To provide qualitative data on the men’s experi-
ence, impact and relative importance of hot ﬂushes as a result of
prostate cancer therapies, with an emphasis on gonadotropin-
releasing hormone (GnRH) agonists. METHODS: A qualitative
study applying a non-probabilistic purposive sampling strategy.
Participants were over 50 years old with histologically conﬁrmed
adenocarcinoma of the prostate, had recently initiated (6
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